China SXT Pharmaceuticals (SXTC) Long-Term Deferred Tax (2018 - 2023)

China SXT Pharmaceuticals (SXTC) has reported Long-Term Deferred Tax for 6 consecutive years, with $652985.0 the latest figure, recorded in Q3 2023.

• Quarterly Long-Term Deferred Tax rose 15.74% year-over-year to $652985.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $652985.0 (up 15.74% YoY) and the FY2023 annual result came in at $552828.0, up 40.99% from the prior year.
• Long-Term Deferred Tax advanced to $652985.0 in Q3 2023 per SXTC's latest filing, from $552828.0 in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for SXTC reached as high as $652985.0 in Q3 2023 and fell as low as $12679.0 in Q3 2019.
• A 5-year average of $293990.7 and a median of $321444.0 in 2021 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2019 — Long-Term Deferred Tax tumbled 72.74% — and 2020, when it jumped 735.6%.
• Year by year, Long-Term Deferred Tax stood at $12679.0 in 2019, then surged by 84.3% to $23367.0 in 2020, then soared by 1275.63% to $321444.0 in 2021, then surged by 75.51% to $564162.0 in 2022, then increased by 15.74% to $652985.0 in 2023.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $652985.0, $552828.0, and $564162.0 for Q3 2023, Q1 2023, and Q3 2022 respectively.